Comparison Of The Expression Of MiR-326 Between Interferon Beta Responders And Non-Responders In Relapsing-Remitting Multiple Sclerosis

• Main Authors: Mahtab Fattahi, Nahid Eskandari, Fattah Sotoodehnejadnematalahi, Vahid Shaygannejad, Kazemi Mohammad
• Format: Article
• Language: English
• Published: Royan Institute (ACECR), Tehran 2020-04-01
• Series: Cell Journal
• Subjects: Interferon-Beta; Lymphocyte; MicroRNA; Multiple Sclerosis
• Online Access: https://celljournal.org/journal/article/fulltext/comparison-of-mir-326-expression-level-between-interferon-beta-responders-and-non-responders-in-relapsing-remitting-multiple-sclerosis-patients.pdf

Objective Multiple sclerosis (MS) is an inflammatory disease resulting in demyelination of the central nervous system (CNS). T helper 17 (Th17) subset protects the human body against pathogens and induces neuroinflammation, which leads to neurodegeneration. MicroRNAs (miRNAs) are a specific class of small (~22 nt) non-coding RNAs that act as post-transcriptional regulators. The expression of the miR-326 is highly associated with the pathogenesis of MS disease in patients through the promotion of Th17 development. Recently, studies showed that disease-modifying therapies (DMTs) could balance the dysregulation of miRNAs in the immune cells of patients with relapsing-remitting MS (RRMS). Interferon-beta (IFN-β) has emerged as one of the most common drugs for the treatment of RR-MS patients. The purpose of this study was to evaluate the expression of the miR-326 in RRMS patients who were responders and non- responders to IFN-β treatment. Materials And Methods In this cross-sectional study, a total of 70 patients (35 responders and 35 non-responders) were enrolled. We analyzed the expression of the miR-326 in peripheral blood mononuclear cells (PBMCs) of RRMS patients at least one year after the initiation of IFN-β therapy. Real-time polymerase chain reaction (RT-PCR) was applied to measure the expression of the miR-326. Results The results showed no substantial change in the expression of the miR-326 between responders and non- responders concerning the treatment with IFN-β. Although the expression of the miR-326 was slightly reduced in IFN-β-responders compared with IFN-β-non-responders; however, the reduction of the miR-326 was not statistically significant. Conclusion Overall, since IFN-β doesn’t normalize abnormal expression of miR-326, this might suggest that IFN-β affects Th17 development through epigenetic mechanisms other than miR-326 regulation.